Den 19. januar 2006 underrettede EuroGen Pharmaceuticals Ltd. officielt Udvalget for Humanmedicinske Lægemidler (CHMP) om, at firmaet havde besluttet at trække sin ansøgning om markedsføringstilladelse for lægemidlet orathecin (rubitecan) tilbage.
On 19 January 2006, EuroGen Pharmaceuticals Ltd officially notified the Agency’ s Committee for Medicinal Products for Human Use (CHMP) of its decision to withdraw its application for marketing authorisation for the medicinal product orathecin (rubitecan).